Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the antitumor efficacy of single-agent brentuximab vedotin (1.8 mg/kg administered intravenously every 3 weeks) as measured by the overall objective response rate (ORR) in patients with relapsed or refractory sALCL following at least 1 multiagent chemotherapy (CHOP or equivalent multiagent chemotherapy regimens with curative intent)
Critère d'inclusion
- Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma